Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Leukemia. 2015 Oct 27;30(3):617–626. doi: 10.1038/leu.2015.302

Figure 4. Genetic ablation of PDE4B limits angiogenesis in vivo.

Figure 4

a) Microvessel density (MVD) of B-cell lymphomas derived from Pde4b+/+ and Pde4b−/− mice was assayed by CD34 immunohistochemistry and shown to be significantly reduced in the Pde4b deficient mice (p<0.0001, two-tailed Student’s t-test). Data shown are mean vessel number from three hot-spots ± SD; each dot in the graph represents a unique tumor (n=19). Representative CD34 IHC of murine B-cell lymphomas are shown in the right panel. The size bar indicates 200 μm. b) Lymphomas arising in Pde4b−/− show significantly lower PI3K activity (left panel) and AKT phosphorylation (T308, quantified by densitometry, right panel) (p<0.0001 and p=0.002, respectively, two-tailed Student’s t-test). Data shown are mean ± SD of an assay performed in triplicate (n=13; 7 Pde4b+/+ and 6 Pde4b−/− lymphomas). c) Lymphomas from Pde4b−/− mice show significantly lower VEGF abundance than tumors arising in Pde4b+/+ mice (p=0.01, two-tailed Student’s t-test). Data shown are mean ± SD of IHC scores (n = 18; 11 Pde4b+/+ and 7 Pde4b−/− lymphomas). Representative VEGF IHC of murine B-cell lymphomas are shown in the right panel. The size bar indicates 200 μm.